First pill targets Cancer's genetic engine in brain tumors
NCT ID NCT02481154
Summary
This early-stage study tested a new oral drug, AG-881, in adults with advanced solid tumors, including a type of brain tumor called glioma, that have specific IDH gene mutations. The main goals were to find a safe dose and see how the body processes the drug. Researchers enrolled 95 patients to first test increasing doses and then expand the group at the most promising dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
MD Anderson Cancer Center
Houston, Texas, 75390, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
UCLA Oncology Center
Los Angeles, California, 90024, United States
-
UT Southwestern Medical Center
Dallas, Texas, 77030, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.